ProblemAAAAI says 25 million Americans have asthma, 5% to 10% may qualify for severe-asthma biologics, and approval delays run past 20 days on average; 47% of waiting patients needed extra prednisone while AMA reports 95% of physicians see care delays.
SolutionAirwayReady gives allergy and pulmonary clinics a biologic-start queue that checks missing eosinophils, IgE, inhaler-failure history, site-of-care rules, benefit path, pharmacy routing, and renewal dates before staff waste hours on payer back-and-forth.
Market opportunityAAAAI represents 7,000+ allergists, severe-asthma biologics carry $20,000-$60,000 yearly list prices, and PA tools already support $500-$5,000 monthly or $5-$15 per-request pricing, so a narrow specialty wedge can sell now.